Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16416854 | 0.85 | SMN1; SMN2 (0.33) | SMN1; SMN2CYP2C9ALDH1A1KDM4EGLA | |
| SCHEMBL20458747 | 0.79 | POLB (0.34) | POLBAPEX1SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL21408397 | 0.79 | KDM4E (0.35) | SMN1; SMN2CYP2C9ALDH1A1KDM4EGLA | |
| SCHEMBL28854915 | 0.74 | POLB (0.34) | POLBAPEX1SMN1; SMN2ALDH1A1MAP2K1 | |
| SCHEMBL16417232 | 0.72 | NR4A2 (0.35) | POLBAPEX1KDM4EHPGD | |
| SCHEMBL17838273 | 0.72 | ALDH1A1 (0.30) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL17838281 | 0.72 | BAZ2B (0.36) | ALDH1A1KDM4EGAAMAP2K1HTT | |
| SCHEMBL16416501 | 0.72 | USP2 (0.37) | POLBAPEX1KDM4E | |
| SCHEMBL28854899 | 0.71 | POLB (0.36) | POLBAPEX1SMN1; SMN2CYP2C9ALDH1A1 | |
| SCHEMBL22906126 | 0.71 | NR4A2 (0.39) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108047115-B | Glyoxylamide-substituted pyrrole amide derivatives and their use as medicaments for the treatment of hepatitis B | 爱尔兰詹森科学公司 | 2021-06-29 | — | — | CN | disclosed |
| US-10450270-B2 | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-10-22 | — | — | US | disclosed |
| EP-3357906-A1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2018-08-08 | — | — | EP | disclosed |
| EP-3024819-B1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-21 | — | — | EP | disclosed |
| US-20160176817-A1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450270-B2 | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | GRHPR, AGXT, GLS2 | POLB 31/4885APEX1 1372/4885SMN1; SMN2 4855/4885 |
| US-20160176817-A1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | GRHPR, AGXT, GLS2 | POLB 31/4885APEX1 1372/4885SMN1; SMN2 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.